Share on StockTwits

Shares of Seattle Genetics (NASDAQ:SGEN) have received an average rating of “Hold” from the thirteen brokerages that are covering the company, American Banking & Market News reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $45.23.

Seattle Genetics (NASDAQ:SGEN) opened at 37.40 on Tuesday. Seattle Genetics has a one year low of $32.35 and a one year high of $55.99. The stock has a 50-day moving average of $37. and a 200-day moving average of $42.31. The company’s market cap is $4.606 billion.

Seattle Genetics (NASDAQ:SGEN) last released its earnings data on Thursday, May 1st. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.08. The company had revenue of $68.30 million for the quarter, compared to the consensus estimate of $64.62 million. During the same quarter in the prior year, the company posted ($0.14) earnings per share. The company’s quarterly revenue was up 19.2% on a year-over-year basis. Analysts expect that Seattle Genetics will post $-0.91 EPS for the current fiscal year.

SGEN has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Seattle Genetics from a “neutral” rating to an “outperform” rating in a research note on Monday, July 7th. They now have a $42.10 price target on the stock. Separately, analysts at Bank of America upgraded shares of Seattle Genetics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 6th. They now have a $40.00 price target on the stock, down previously from $46.00. Finally, analysts at Cantor Fitzgerald raised their price target on shares of Seattle Genetics from $24.00 to $28.00 in a research note on Friday, May 2nd.

Seattle Genetics, Inc is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.